Currently approved adjuvants induce protective Ab responses but are more limited for generating cellular immunity. In this study, we assessed the effect of combining two adjuvants with distinct mechanisms of action on their ability to prime T cells: the TLR3 ligand, polyinosinic:polycytidylic acid (poly I:C), and immunostimulatory complexes (ISCOMs). Each adjuvant was administered alone or together with HIV Gag protein (Gag), and the magnitude, quality, and phenotype of Gag-specific T cell responses were assessed. For CD8 T cells, all adjuvants induced a comparable response magnitude, but combining poly I:C with ISCOMs induced a high frequency of CD127 + , IL-2-producing cells with decreased expression of Tbet compared with either adjuvant alone. For CD4 T cells, combining poly I:C and ISCOMs increased the frequency of multifunctional cells, producing IFN-g, IL-2, and TNF, and the total magnitude of the response compared with either adjuvant alone. CD8 or CD4 T cell responses induced by both adjuvants mediated protection against Gag-expressing Listeria monocytogenes or vaccinia viral infections. Poly I:C and ISCOMs can alter Ag uptake and/or processing, and we therefore used fluorescently labeled HIV Gag and DQ-OVA to assess these mechanisms, respectively, in multiple dendritic cell subsets. Poly I:C promoted uptake and retention of Ag, whereas ISCOMs enhanced Ag degradation. Combining poly I:C and ISCOMs caused substantial death of dendritic cells but persistence of degraded Ag. These data illustrate how combining adjuvants, such as poly I:C and ISCOMs, that modulate Ag processing and have potent innate activity, can enhance the magnitude, quality, and phenotype of T cell immunity. The Journal of Immunology, 2013, 191: 5085-5096. P reventive vaccination against HIV, malaria, and tuberculosis will require induction of potent Ab responses, T cell responses, or both for optimal protection (1) (2) (3) (4) . Because humoral and cellular immune responses can wane following vaccination, continued boosting may be required to maintain responses above a threshold necessary to mediate protection. Protein-based vaccines given with adjuvants are one approach that can be used in combination with other vaccine platforms for priming and/or boosting adaptive immunity. Currently approved clinical adjuvant formulations include alum and oil/water emulsions, which elicit protective humoral immunity, but are far less potent for inducing CD4/Th1 or CD8 T cell immunity [reviewed in (5) ]. Improving cellular immunity with protein-based vaccination will require adjuvants that elicit potent innate cytokines conducive to induction of cellular responses and efficient Ag presentation. Polyinosinic:polycytidylic acid (poly I:C) and immunostimulatory complexes (ISCOMs) are two adjuvants that show promise in preclinical studies and early clinical trials for induction of both Ab and T cell responses (6) (7) (8) (9) .
Poly I:C is a synthetic dsRNA analog and a ligand for multiple pathogen recognition receptors, including TLR3, melanoma differentiation-associated protein 5, retinoic acid-inducible gene 1, and dsRNA-dependent protein kinase R (10) (11) (12) (13) (14) . Expression of TLR3 is endosomal and found predominantly in CD8a + dendritic cells (DCs) or langerin + dermal DCs (dDCs) (15, 16) , whereas melanoma differentiation-associated protein 5, retinoic acid-inducible gene 1, and protein kinase R localize to the cytosol and are more broadly expressed on APCs and nonhematopoietic stromal cells (6, 17, 18) . Poly I:C stimulates rapid production of IL-6, IL-10, IL-12 p40, MCP-1, TNF, type I IFN, and IFN-g, resulting in significant DC and NK cell activation (6, 19) . When coadministered with protein Ag, poly I:C potently primes CD4/Th1 cell and Ab responses (6, 7, 20) and promotes cross-presentation of Ag to CD8 T cells by DCs through TLR3 signaling (21) .
ISCOM particles are cage-like structures that assemble from cholesterol, phospholipids, and saponins [reviewed in (22) ]. ISCOMs can enhance Ag delivery to APCs when Ag is incorporated into the particle, but ISCOMs do not function solely as delivery vehicles, because certain fractions of saponin possess intrinsic adjuvant activity (23) . ISCOMs have been shown to induce caspase-dependent cleavage of IL-1b and robust serum production of IL-5, IL-6, GM-CSF, and IL-12 p40 (24, 25) . As a result, ISCOMs prime potent long-lived Ab responses with a balanced CD4 Th1/Th2 T cell response (26) and low-level induction of CTLs. ISCOMs lead to cross-presentation most likely as a result of disruption of the integrity of phagolysosomes after endocytosis, which could permit access of Ag to the cytosol (27, 28) . Cross-presentation with ISCOMs in vitro is most efficient with monocyte-derived DCs (28), although ex vivo CD8a + DCs are responsible for the majority of Ag presentation to CD8 T cells (25) .
A combination of poly I:C and ISCOMs could potentiate the effect of each adjuvant by activating distinct, but complimentary innate signaling and Ag-processing pathways. Prior studies using combined ligands for distinct TLRs have demonstrated enhanced innate or adaptive immunity in vitro (29) and in vivo (30) . Poly I:C has been used in combination with particulate delivery systems, such as liposomes, and combined with other TLR agonists, such as CpG, to enhance innate signaling and priming of T cells (31, 32) . ISCOMs have also been used in combination with CpG, which enhanced cross-priming of tumor Ag (33) and induced robust HIV Env-specific humoral immunity (34) . However, a combination of poly I:C with ISCOMs has not been evaluated.
For this study, we hypothesized that combining poly I:C and ISCOMs would result in more potent T cell immunity than either adjuvant alone. We show that combining the adjuvants increased CD4/Th1 cell responses and enhanced the qualitative and phenotypic profile of CD8 T cell responses by increasing expression of CD127 and IL-2. Combining poly I:C with ISCOMs also resulted in rapid initial degradation but prolonged retention of Ag, which may represent a mechanism contributing to the observed effects on T cells. Overall, the data presented show how combining adjuvants with distinct effects on innate cytokine production and Ag presentation can enhance T cell immunity with protein-based vaccines.
Materials and Methods
Mice BALB/c, C57BL/6, or Batf3 2/2 (C.129S-Batf3tm1Kmm/J) mice were obtained from The Jackson Laboratory (Bar Harbor, ME) and housed at the Vaccine Research Center Biomedical Research Unit (Bethesda, MD). Mice were 6-12 wk old at the time of vaccination. All experimental animal protocols were approved by the Vaccine Research Center Animal Care and Use Committee.
Formulations and vaccinations
Formulations were prepared using 30 mg HIV-Gag p41 protein (Gag) (Protein Sciences, Meriden, CT), which was mixed with 12 mg Abisco100 ISCOMs (Isconova AB, Stockholm, Sweden) and/or 50 mg poly I:C (Invivogen, San Diego, CA) immediately prior to vaccination. In Supplemental Fig. 3 , 50 mg CpG 1826 (Pfizer, New York, NY) was used. The ISCOM dose was chosen based on manufacturer's recommendation, and the poly I:C, CpG, and protein doses were chosen based on dose titrations to maximize T cell responses.
Following purification of Gag protein, it was treated with Triton X-100 to remove residual endotoxin and was validated at ,0.1 endotoxin units with an Endpoint Chromogenic LAL Assay (Lonza, Basel, Swizerland), as has been performed for prior studies (35, 36) . AbISCO100 is a Matrix formulation that is mixed with Ag in solution and, as such, the Ag is not incorporated in the structure. All formulations were prepared in PBS and then administered s.c. in both hind footpads, given as a 100 mL dose split into 50 mL per footpad. Two doses were administered 3 wk apart.
To assess Ag uptake and degradation experiments, 30 mg HIV Gag Alexa Fluor (AF) 488 (conjugated by Molecular Probes/Life Technologies, Grand Island, NY), full-length OVA-AF488 (Molecular Probes), or DQ-OVA (Molecular Probes) was used.
To assess boosting of primed CD8 T cell responses, 1 3 10 8 particle units of replication-deficient adenovirus rAd5:Gag was given i.m. as a 100 mL dose into the left gluteal muscle (37) .
Tetramer staining
For assessment of killer-cell lectin-like receptor subfamily G1 (KLRG1) and CD127 expression, splenocytes were harvested and stained, as previously described (37), using a PE-labeled H-2Kd tetramer loaded with the immunodominant HIV Gag peptide (AMQMLKETI) (38) . For assessment of Tbet expression, splenocytes were stained with LIVE/DEAD Fixable Violet viability dye (Life Technologies), blocked with anti-FcgRIII Ab (clone 2.4G2; 5 mg/ml; BD Pharmingen), surface stained with PE-labeled tetramer, anti-CD8 allophycocyanin-Cy7 (clone 53-6.7; BioLegend) and anti-CD62L PE-Cy7 (clone MEL-14; Abcam), fixed, permeabilized with Fix/Perm and Perm/Wash Buffers (eBiosciences), and intracellularly stained with anti-CD3 PerCP-Cy5.5 5 (clone 145-2C11; BD Pharmingen) and anti-Tbet-AF647 (eBiosciences).
Intracellular cytokine staining
For assessment of Ag-specific cytokine production, splenocytes were harvested and restimulated in vitro, as previously described (37), using a peptide pool comprising 15-mers spanning HIV Gag p41 (each at 2 mg/ml) or fulllength HIV Gag p41 protein (20 mg/ml). For evaluation of IFN-g, IL-2, TNF, and IL-10 production, samples were then stained, as previously described (37) . Alternatively, for evaluation of IL-17 production, samples were stained, as previously described, except anti-IL-2 FITC (clone JES6-5H4; BD Pharmingen) and anti-IL-17A PE (clone TC11-18H10; BD Pharmingen) Abs were substituted for anti-IL-10 AF488 and anti-IL-2 PE Abs during intracellular staining.
DC preparation and staining
Following vaccination, both popliteal lymph nodes were harvested and pooled from eight (Gag:AF488 staining) or four (DQ-OVA staining) individual mice for each formulation. DCs were harvested by enzymatic digestion and enriched by MACS CD11c positive selection, as previously described (39) . Cells were then stained with LIVE/DEAD Fixable AquaBlue viability dye (Life Technologies) and stained by one of two panels, as follows: 1) Gag:AF488 staining, surface staining for B220-Cy7PE (clone RA3-6B2; BD Pharmingen), CD8-allophycocyanin Cy7 (clone 53-6.7; BioLegend), CD11b-AF700 (clone M1/70; BioLegend), Pan-NK-PacificBlue (clone DX5; BioLegend), CD19-PacificBlue (clone 6D5; BioLegend), CD11c-PE (clone HL3; BD Pharmingen), CD103-PerCPCy5.5 (clone 2E7; BioLegend), and DEC205 biotin (clone NLDC-145; Miltenyi Biotec), followed by streptavidin-TexasRedPE (BD Pharmingen), followed by intracellular staining for CD3-PECy5 (clone 145-2C11; BD Pharmingen) and Langerin-AF647 (clone 929F3.01; Dendritics, Lyon, France); 2) DQ-OVA staining, surface staining for B220-Cy7PE, CD8-allophycocyanin Cy7, CD11b-AF700, Pan-NK-PacificBlue and CD19-PacificBlue, CD11c-QD605 (clone HL3; conjugated in house), followed by intracellular staining for CD3-allophycocyanin (clone 145-2C11; BD Pharmingen). DC numbers were back calculated to represent cells recovered per lymph node.
Multiparameter flow cytometry
Samples were resuspended in 0.5% paraformaldehyde before acquisition using a modified LSR II flow cytometer (BD Biosciences). Results were analyzed using FlowJo version 9.3, Pestle version 1.6.2, and SPICE version 5.22 software (M. Roederer, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health). Background cytokine staining was subtracted, as defined by staining in samples incubated without peptide or protein.
Infections and Ab-mediated depletions
For infectious challenge, attenuated Listeria monocytogenes (DactA, DintB) or vaccinia virus (thymidine kinase-deficient Western Reserve strain) was used, each expressing Gag from HIV-1 strain HXBX or strain IIIB, respectively. Infections were performed, as previously described (37), using a 2 3 10 7 CFU dose of L. monocytogenes expressing Gag (Listeria:Gag) or a 6.5 3 10 6 PFU dose of vaccinia virus expressing Gag (rVACV:Gag). Ab-mediated depletion of CD8 and/or CD4 T cells, after vaccination and prior to challenge, was performed, as previously described (37) . Depleting Abs were provided by F. Finkelman (University of Cincinnati, Cincinnati, OH).
Statistics
Statistical significance was calculated using a two-tailed Wilcoxon rank sum test using SPICE software or a two-tailed Mann-Whitney U test using PRISM software.
Results

Vaccination schedule
To assess the effect of combining poly I:C and ISCOMs on the generation of T cell responses, we formulated each adjuvant alone or in combination using HIV-Gag protein (Gag) in BALB/c mice (Fig. 1A ). ISCOMs were used as ISCOM-Matrix formulations, in which there is no defined physical association between the ISCOM and the Ag. Two doses of each formulation were administered s.c. in both rear footpads, 3 wk apart (Fig. 1A) . At the peak response (10 d after the second dose), the magnitude, quality, and phenotype of Gag-specific CD8 and CD4 T cell responses were assessed using multiparameter flow cytometry after MHC class I tetramer staining and/or intracellular cytokine staining (ICS) (Fig. 1A ).
Poly I:C and/or ISCOMs induce CD8 T cell responses of similar magnitude but distinct phenotype
The frequency of Gag-specific CD8 T cell responses by tetramer staining was similar when Gag was given with poly I:C alone, ISCOMs alone, or poly I:C with ISCOMs (Fig. 1B) . We next assessed the phenotype of tetramer + CD8 T cells using CD127, the IL-7R a-chain, and KLRG1. Differential expression of these markers can delineate populations of short-lived effector cells (40) and memory precursor effector cells (41) . In addition, CD127 + KLRG1 + CD8 T cells are a population of durable long-term memory cells induced following viral vaccination or prime-boost vaccination (37, 42) . Formulations that contained ISCOMs induced a significantly higher proportion (∼70-80%) of CD8 T cells expressing CD127 with or without KLRG1 (Fig. 1C , black arc) compared with poly I:C alone (∼50%).
Expression of the transcription factor Tbet is strongly induced with IL-12 signaling and can alter the differentiation, stability, and functional capacity of CD8 T cells (40, 43) . Tbet expression was upregulated in Gag-specific CD8 T cells after vaccination with any of the adjuvants relative to the total CD8 T cell population in naive mice used as a negative control (Fig. 1D ). Poly I:C alone induced the highest median fluorescence intensity (MFI) for Tbet expression, followed by ISCOMs alone (Fig. 1D , right panel), but poly I:C with ISCOMs induced a significantly lower MFI compared with either adjuvant alone (Fig. 1D, right panel) . These data show that combining poly I:C and ISCOMs primes a CD8 T cell population that is distinct in terms of phenotype and transcription factor expression from that induced by either adjuvant alone.
Poly I:C and/or ISCOMs induce qualitatively different CD8 T cell responses
Using multiparameter flow cytometry following in vitro restimulation with overlapping Gag peptides, we showed that all adjuvants induced a comparable frequency of Gag-specific CD8 T cells as assessed by total cytokine (IFN-g, IL-2, and TNF) production (Fig. 1E) . These data are consistent with the magnitude of Gagspecific CD8 T cell responses observed by tetramer staining (Fig.  1B) . Interestingly, formulations that contained ISCOMs significantly increased the frequency of IL-2-producing cells relative to poly I:C alone (Fig. 1F ), highlighting differences in the cytokine profile of Gag-specific CD8 T cells.
To extend these findings, we assessed the quality of Gag-specific CD8 T cell responses using the relative frequency of cells producing any combination of IFN-g, IL-2, and TNF at the singlecell level (44, 45) . Poly I:C alone induced predominantly IFN-g + TNF + or IFN-g + Gag-specific CD8 T cells (Supplemental Fig. 1A ) and a low frequency (Supplemental Fig. 1A ) and proportion (Fig.  1G, 3 + , black sector) of multifunctional cells, which can produce all three cytokines (IFN-g, IL-2, and TNF). These data are consistent with the low frequency of IL-2-producing CD8 T cells observed in Fig. 1F . ISCOMs alone and poly I:C with ISCOMs induced a high frequency (Supplemental Fig. 1A ) and proportion (Fig. 1G, 3 + , black sector) of multifunctional cells. However, ISCOMs alone also induced a significantly higher frequency (Supplemental Fig. 1A ) and proportion (Fig. 1G, black Taken together, these data illustrate that for CD8 T cells, poly I:C promotes production of IFN-g, whereas ISCOMs promote production of IL-2.
CD8 T cells primed by poly I:C and/or ISCOMs are potently boosted by rAd5
Given that combining poly I:C and ISCOMs altered the quality and phenotype of CD8 T cells, we assessed the durability of these cells and their ability to respond to subsequent stimulation in vivo following a boost with a viral vector. CD8 T cell responses were evaluated 6 wk after priming, and the frequency of Gagspecific CD8 T cells had contracted markedly compared with the peak response, but responses were still comparable across all adjuvants (Fig. 1H) . To evaluate the ability of primed CD8 T cells to expand in vivo, mice were boosted with 1 3 10 8 PU rAd5:Gag 4 wk after priming, and responses were assessed 2 wk later. The frequency of Gag-specific CD8 T cells was significantly higher in groups that had been primed with any of the adjuvanted vaccines compared with mice primed with PBS or Gag alone (Fig. 1I) . Additionally, the frequency of Gag-specific CD8 T cells in mice primed with poly I:C with ISCOMs was significantly higher compared with poly I:C alone and trended higher compared with ISCOMs alone (Fig. 1I) . Thus, formulations containing ISCOMs prime CD8 T cell populations that are more responsive to subsequent boosting, and this may be further enhanced with inclusion of poly I:C.
Combining poly I:C with ISCOMs increases the magnitude of multifunctional CD4 T cell responses
We next assessed the magnitude and qualitative profile of Gagspecific CD4 T cell responses. Poly I:C with ISCOMs primed significantly higher total cytokine responses than either adjuvant alone ( Fig. 2A) . ISCOMs alone induced a significantly lower frequency of IFN-g-producing cells than formulations containing poly I:C (Fig. 2B ). This resulted in marked differences in the quality of CD4 T cell cytokine responses. Poly I:C alone induced a high proportion of multifunctional cells (Fig. 2C, 3 + , black sector), whereas ISCOMs alone primed predominantly IL-2 + TNF + , IL-2 + or TNF + CD4 T cells (Supplemental Fig. 1B ), which are populations that do not produce IFN-g (Fig. 2C, IFN-g 2 , black arc). Poly I:C with ISCOMs induced a high frequency and proportion of IL-2 + TNF + and multifunctional CD4 T cells (Supplemental Fig. 1B, Fig. 2C ), reflecting the qualitative profiles of both adjuvants. In general, we observed a clear polarization bias, in which poly I:C promoted a strong Th1 response with a higher proportion of IFN-g-producing CD4 T cells compared with ISCOMs. When we assessed the durability of CD4 T cells, responses had contracted modestly (1-to 2-fold) but comparably across adjuvant formulations by 6 wk after priming (Fig. 2D) .
IFN-g, IL-2, and TNF are critical cytokines for Th1 immunity and protection with a variety of intracellular pathogens. As noted above, poly I:C potently induced IFN-g production in CD4 T cells, most likely due to induction of IL-12 and type I and II IFNs (6) . By contrast, CD4 T cell responses induced by ISCOMs were less polarized toward IFN-g production and Th1 immunity. Given the heterogeneity of CD4 T cell responses, we assayed for additional cytokines that may regulate responses or provide alternative effector function.
IL-10 produced by CD4 T cells can regulate and promote resolution of immune responses [reviewed in (46) ]. IL-10 was detected with all adjuvant formulations (Fig. 2E) , and the frequencies of IL-10-producing CD4 T cells were proportionate to the frequencies of total cytokine response for each adjuvant (Fig. 2A) . Both vaccines (47) and infections (48) can induce CD4 T cells that simultaneously induce Th1 cytokine and IL-10 production, and this may be a mechanism for self-regulation.
ISCOMs induce production of IL-1b (24, 25) , which promotes induction of Th17 CD4 T cells in combination with IL-6 (49), and induction of IL-17 + CD4 T cells has been observed after ISCOM vaccination (50). We did not detect IL-17 production after vaccination with poly I:C alone, but did detect low and comparable frequencies of IL-17 + CD4 T cells after ISCOM vaccination, with or without poly I:C in several experiments (Fig.  2F) . The biologic importance of such responses remains to be determined.
Protection against Listeria and vaccinia is mediated by CD8 and CD4 T cell responses, respectively
Given the qualitative and quantitative differences in Gag-specific T cell responses after vaccination, we assessed the ability of these responses to confer protection against bacterial or viral challenge. Mice were vaccinated and then challenged 6 wk later with recombinant L. monocytogenes or vaccinia virus expressing Gag (Listeria: Gag and rVACV:Gag, respectively).
After i.v. challenge with Listeria:Gag, spleens were harvested and bacterial load was evaluated. Mice primed with any of the adjuvants had a significant but comparable reduction in bacterial load compared with PBS control or Gag alone (Fig. 3A) . After vaccination with poly I:C with ISCOMs, depletion of CD8 but not CD4 T cells abrogated protection (Fig. 3B) . As all adjuvants induced comparable Gag-specific CD8 T cell responses (Fig. 1B,  1D ), these results are consistent with a prior study showing that the magnitude of CD8 T cell responses correlates with protection in this model (37) .
As an alternative viral challenge model, rVACV:Gag was given intranasally and body weight was followed over 6 d as a measure of disease severity. Mice primed with Gag alone or the PBS control exhibited a marked loss of body weight; however, mice primed with either poly I:C or ISCOMs alone similarly and significantly attenuated loss of body weight (Fig. 3C) . Strikingly, mice primed with poly I:C with ISCOMs maintained their original body weight and were significantly higher than weights observed in mice primed with poly I:C or ISCOMs alone (Fig. 3C) . After vaccination with poly I:C with ISCOMs, depletion of CD4 T cells caused significantly more weight loss than observed in a controltreated animal, although not to the same level as the PBS control, whereas depletion of CD8 T cells caused a mild but not significant loss of weight (Fig. 3D) . These data suggest that protection against rVACV:Gag is predominantly dependent on CD4 T cells, with some contribution by CD8 T cells and possibly Ab responses. This is consistent with the observation that poly I:C with ISCOMs induced Gag-specific CD4 T cell responses of higher frequency than poly I:C or ISCOMs alone.
In summary, in these acute infection models, protection correlates directly with magnitude of the relevant T cell response: CD8 for Listeria:Gag and CD4 for rVACV:Gag. It is possible that the qualitative differences in T cell responses induced by different adjuvant formulations would have more impact on protection against more chronic infections.
Poly I:C and ISCOMs differentially alter recruitment of DC subsets to the draining lymph node
The quantitative and qualitative differences in T cell responses reflect early activation signals received by T cells from APCs and the innate environment at the site of priming. Poly I:C is a strong inducer of type I IFN, which we have previously shown to enhance trafficking and uptake of Ag by DCs after adjuvanting with a TLR7 ligand (39) . Moreover, ISCOMs disrupt phagolysosomes upon endocytosis by APCs and can alter Ag distribution within Ag-processing compartments (27, 28) . Accordingly, we focused on whether poly I:C, ISCOMs, or the combination of adjuvants altered Ag uptake, processing, and presentation by DC subsets that could subsequently influence priming of T cell immunity.
To assess the kinetics of DC subsets in the draining lymph node (dLN) after vaccination and their potential for Ag uptake, we admin- istered each adjuvant formulation with Gag protein fluorescently labeled with AF488 (Gag:AF488). The dLN were harvested, pooled, and processed at 24, 48, 72, and 168 h (1, 2, 3, or 7 d) after vaccination. Samples were stained with a 12-color multiparameter flow cytometry panel that enables us to identify six DC subsets present in murine skin dLNs: the lymph node-resident CD8a + DCs and plasmacytoid DCs (pDCs), as well as the migratory populations such as monocyte-derived DCs, langerin + and langerin 2 dDCs, and Langerhans cells (Fig. 4A ).
The dLN must be pooled to detect rare DC populations, which limits statistical analysis between the groups, but the data presented are representative of three independent experiments with similar results. After vaccination, there was a gradual increase in the number of total CD11c + DCs recovered after vaccination with Gag alone, poly I:C alone, and ISCOMs alone compared with the PBS control or naive (data not shown) mice at 24 h (Fig. 4B) . In contrast, the number of total CD11c + DCs decreased relative to the PBS control after vaccination with poly I:C with ISCOMs at 24 h (Fig. 4B) , and there was a higher number (Fig. 4C) and proportion (Fig. 4C, inset) of dead leukocytes. This suggests that poly I:C given with ISCOMs induced death of CD11c + DCs in the dLN. Upon assessment of DC subset composition in the dLN, we observed that the number (Fig. 4D, bar graph) and relative frequency (Fig. 4D , pie graph) of pDCs declined markedly by 24 h after vaccination in all adjuvanted vaccines compared with PBS or Gag alone. This has been observed after vaccination with other adjuvants, such as CpG in a protein subunit vaccine (51) , and may represent mobilization to the blood or death of pDCs. Other DC subsets sequentially increased in number and relative frequency for all formulations: first, monocyte-derived DCs at 24 h, langerin + and langerin 2 dDCs at 48 h, and then Langerhans cells at 72 h (Fig. 4D) , reflecting sequential migration of skin-derived DC subsets to the dLN after vaccination. Of note, vaccination with ISCOM formulations increases the relative frequency of monocytederived DCs at 48 h, and the number and relative frequency of monocyte-derived DCs remain elevated at 168 h after vaccination (Fig. 4D) , which was the last time point assessed. This highlights that ISCOMs induce prolonged recruitment of certain cell subsets, and monocyte-derived DCs in particular, to the dLN.
Adjuvants modify uptake of Ag by DC subsets following vaccination
When uptake of Gag:AF488 was assessed, more Gag:AF488 + CD11c + DCs were recovered after vaccination with poly I:C alone compared with Gag alone at all time points (Fig. 4E ), and Gag: AF488 was still detected 168 h after vaccination (Fig. 4E, inset) . This is consistent with our previous study in which a TLR7 ligand induced type I IFN production and thereby increased Ag uptake (39) . In marked contrast, we recovered low numbers of Gag: AF488 + CD11c + DCs from mice that received formulations containing ISCOMs at all time points after vaccination (Fig. 4E) . When DC subsets were assessed for Ag uptake at 24 h after vaccination, Gag:AF488 localized predominantly to langerin 2 dDCs and monocyte-derived DCs for Gag alone or poly I:C alone, with very low but detectable uptake by CD8a + DCs (Fig. 4F ). In mice that had received ISCOMs with or without poly I:C, there was a very low number of total Gag:AF488 + DCs (Fig. 4F , bar graphs), but there were higher proportions of Gag:AF488 + CD8a + DCs, Langerhans cells, and langerin + dDCs compared with Gag alone or poly I:C alone (Fig. 4F, pie graphs) . At subsequent time points, distribution of detectable Ag remained similar to the 24-h time point for each formulation (data not shown).
These data were collected using BALB/c mice and fluorescently labeled Gag Ag. Similar results were obtained in C57BL/6 mice with fluorescently labeled OVA Ag (Supplemental Fig. 2 ), demonstrating that changes in dLN DC composition and Ag uptake are not mouse strain or Ag specific.
ISCOMs induce rapid processing of Ag by DCs, but poly I:C promotes retention of peptide
The limited ability to detect Gag:AF488 in CD11c + DCs after vaccination with ISCOMs could be due to two distinct mechanisms, as follows: ISCOMs may limit uptake of Ag by DCs or promote rapid degradation of Ag and loss of the AF488 fluorescent signal. To examine the rate of degradation of Ag in vivo after vaccination, we used DQ-OVA. DQ-OVA has high-density BOD-IPY fluorophore residues arrayed along the OVA protein, which self-quench when the protein is intact but fluoresce when the protein undergoes degradation (52, 53) .
We simplified the analysis to identify three dLN DC populations, as follows: CD8a + DCs, pDCs, and migratory DCs, to include the monocyte-derived DCs, Langerhans cells, and langerin 2 and langerin + dDCs (Fig. 5A ). Because Gag:AF488 signal is already low at 24 h after vaccination with ISCOM formulations (Fig. 4E) , dLNs were harvested from BALB/c mice at 10, 24, and 72 h after vaccination.
Mice that received ISCOMs alone had a higher number (Fig.  5B) and frequency (Fig. 5C , top and middle rows) of DQ-OVA + CD11c
+ DCs at 10 and 24 h after vaccination. Mice that received poly I:C with ISCOMs had low numbers of DQ-OVA + DCs compared with ISCOMs alone at 10 and 24 h after vaccination (Fig. 5B ), but both groups had comparable proportions of DCs that contained DQ-OVA (Fig. 5C, top and middle rows) . At early time points after vaccination with poly I:C with ISCOMs, we observed significant cell death in the dLN (Fig. 4C) , suggesting that the low number of DQ-OVA + DCs is most likely due to low viability. Interestingly, we consistently observed an elevated number ( + DCs, but not detected in pDCs (Fig. 5D ). Thus, ISCOMs increase the rate of Ag degradation relative to poly I:C or protein alone, but inclusion of poly I:C with ISCOMs promotes persistence of degraded Ag. (39, (56) (57) (58) and, as such, would be most likely required to mediate priming of CD8 T cells with a protein-based vaccine. Indeed, Gag-specific CD8 T cell cytokine responses were completely abrogated in Batf3 2/2 mice compared with wild-type (WT) mice for all adjuvant formulations (Fig. 6A) . For CD4 T cells, Batf3 2/2 mice trended toward lower Gag-specific cytokine responses for poly I:C with or without ISCOMs and were significantly lower for ISCOMs alone compared with WT mice (Fig. 6B) . Overall, CD8a + DCs and langerin + dDCs are essential for CD8 T cell responses with poly I:C and/or ISCOMs and may play a role for optimizing CD4 T cell responses with ISCOMs.
Discussion
Poly I:C and ISCOMs have been used individually in protein-based vaccines to enhance humoral and cellular immunity in preclinical and human studies. We focused on poly I:C as an adjuvant based on recent studies in nonhuman primates, showing that it elicits potent SIV or HIV Gag T cell responses when given with protein-based or DC-targeting vaccines (7, 59) . Moreover, poly I:C formulated with poly-lysine and carboxymethylcellulose to enhance stability has been used as an investigational reagent in humans and shown to have potent innate activity (60) . ISCOM-Matrix vaccines and vaccines containing the saponin derivative QS21 have been well tolerated, protective, and generated Ab and T cell responses in human clinical trials (8, 9, 61) . We also noted a significant increase in Gag-specific serum IgG when poly I:C and ISCOMs were combined, but we focused in this study on quantitative and qualitative differences in T cell immunity and adjuvant mechanisms that may contribute to these differences, due to the difficulty in inducing potent T cell responses with protein-based vaccines in humans.
Poly I:C potently induces type I IFN, and coadministration of poly I:C with Gag in this study led to more DCs loaded with detectable Ag (Fig. 4D) . These data are consistent with our previous study using a TLR7 ligand adjuvant, which promoted type I IFN-dependent uptake of Ag by DCs (39) . In addition to Ag uptake, in vitro production of type I IFN by poly I:C promotes retention of degraded Ag by DCs (62) . Of note, CpG also induces robust type I IFN production and can prolong Ag retention and presentation in vitro (63) . Consistent with this in vitro observation, poly I:C prolonged the presence of degraded Ag in DCs in vivo in this study (Fig. 5B, 5C ), and this correlated with increased CD4 T cell responses after vaccination with the combination of poly I:C and ISCOMs (Fig. 2) . Other studies have combined CpG with ISCOMs and observed increased CD4 T cell immunity (33) . As CpG is also a potent inducer of type I IFN in vivo, we confirmed that combining CpG with ISCOMs induced quantitative and qualitative changes that were similar to poly I:C (Supplemental Fig. 3) . Thus, our results suggest that type I IFN generated by poly I:C, and possibly CpG, acts on DCs in vivo to prolong retention of degraded Ag and thereby enhance expansion of Ag-specific CD4 T cell responses.
ISCOMs were shown to accelerate Ag degradation in this study, which is most likely the result of two possible and not mutually exclusive mechanisms. Ag codelivered with ISCOMs can enter the cytosol during disruption, whereupon Ag can be rapidly degraded by tripeptidyl peptidase II (28) . Alternatively, disruption of phagolysosomal integrity could trigger cellular death, during which cellular contents, including Ag, may be degraded, taken up, and presented by other APCs. When poly I:C and ISCOM were combined, we observed a high number and frequency of dead leukocytes soon after vaccination (Fig. 4C) . Additionally, we found that Batf3 expression, and presumably CD8a + DCs and langerin + dDCs, was required for CD8 T cell responses (Fig. 6A) , despite the fact that these DCs were relatively minor populations for Ag uptake and degradation (Figs. 4, 5 ). These data imply that a very low number of such DCs is required to directly present Ag or mediate cross-presentation. It was also notable that CD8a + DCs and langerin + dDCs were required for optimal CD4 T cell responses after ISCOM vaccination (Fig.  6B) . Taken together, we speculate that APCs that initially take up Ag are not optimal for direct presentation to CD4 T cells, possibly due to reduced cell viability. Subsequent uptake of cellular debris with Ag by CD8a + DCs and langerin + dDCs could facilitate both cross-presentation and MHC class II presentation.
Aside from DCs and T cells, other innate cells may shape the development of adaptive immunity with poly I:C and ISCOMs. In particular, elevated numbers of neutrophils have been observed in the dLN after ISCOM vaccination (25) , which we also observed in this study (Supplemental Fig. 4A ). Neutrophils may prime or cross-prime naive TCR transgenic CD4 and CD8 T cells directly in vivo (64, 65) , but neutrophils also undergo cell death in dLNs (66) and may therefore ferry Ag to secondary lymphoid sites. We also observed increased and prolonged recruitment of macrophages and monocytes (Supplemental Fig. 4B, 4C ) and sustained recruitment of monocyte-derived DCs with the combination of poly I:C and ISCOMs. Ag presentation by these APC subsets has been shown to increase T cell responses and promote qualitative changes such as increased TNF production (67), consistent with our study.
Regardless of the mechanism, the rapid degradation of Ag would provide an immediate bolus of Ag presentation after ISCOM vaccination. High Ag density on APCs can engage T cells with lower-affinity TCRs (68, 69) , but subsequent depletion of Ag can alter CD8 T cell differentiation to increase IL-2 and TNF production and increase CD127 expression, as observed in a L. monocytogenes infection model (70) . We speculate that this also occurs after ISCOM vaccination, with rapid presentation of a high density of Ag that is subsequently depleted, leading to CD8 T cell responses with high IL-2 and TNF production and high CD127 expression, as observed in this study.
Innate signaling induced by poly I:C or ISCOMs could directly influence the magnitude of T cell responses. Although not directly assessed in this work, a number of prior studies have clearly shown that poly I:C is a potent inducer of type I and II IFNs and IL-12 in vivo (6, 11), which leads to polarized Th1 responses and promotes expansion and survival of CD8 T cells (71) (72) (73) . Alternatively, ISCOMs have been shown to elicit IL-1b production (24, 25) , which can directly signal to CD4 T cells in vitro to augment proliferation (71) . Concurrent treatment of CD4 T cells in vitro with type I IFN and IL-1ab has been shown to increase cytokine responses (74) ; thus, cytokines induced by poly I:C and ISCOMs may work in concert to enhance the magnitude of CD4/Th1 responses and the quality of CD8 T cell responses.
In conclusion, the combination of poly I:C and ISCOMs resulted in protective T cell immunity against bacterial and viral infections. These data highlight that adjuvants not only have a major role for enhancing T cell responses through innate cytokines, but also have profound effects on DC trafficking, Ag uptake, and kinetics of Ag presentation. We speculate that differences in Ag degradation with the inclusion of ISCOMs and retention of Ag with the inclusion of poly I:C may contribute to differences in the magnitude and quality of T cell responses. As a result, the robust T cell responses induced by combining poly I:C and ISCOMs are most likely shaped by the collective effects of Ag presentation and innate signaling. To enhance rational design of subunit vaccines, the net effect of multiple mechanisms altering Ag processing and innate signaling can be harnessed to augment T cell immunity.
